|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 799 9th St NW |
Address2 | Suite 210 |
| City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Irving |
State | TX |
Zip Code | 75062 |
Country | USA |
|
5. Senate ID# 40021-00012
|
||||||||
|
6. House ID# 313240000
|
||||||||
| TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Shoshana Krilow |
Date | 1/19/2021 4:07:35 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
COVID-19 crisis - Engaged with Congress and the administration to advocate for greater regulatory flexibility and appropriate reimbursement for hospitals through development, passage and ongoing implementation of coronavirus relief legislation:
HEROES Act (HR 6800)
Heroes Act 2.0 (H.R. 925)
Health, Economic Assistance, Liability Protection and Schools (HEALS) Act (S. 178)
The Consolidated Appropriations Act (H.R. 133)
Telehealth - Urged Congress and the administration to make permanent telehealth flexibilities related to distant site and geographic limitations, expanding provider types and services available to consumers and maintain Medicare reimbursement parity.
Accelerated and Advanced Payment Program - Advocated for Congress and the administration to offer forgiveness for accelerated and advanced payments during the COVID-19 public health emergency. Offered support for reduced interest rates, extended loan repayment period and reduced recoupment amounts (S. 3750/H.R. 6837/ H.R. 8337 / H.R. 133).
Medicaid Disproportionate Share Hospital (DSH) Payments - Urged Congress to end or further delay implementation of Medicaid DSH payment cuts.
Medicare Sequester - urged Congress to end or further delay ongoing Medicare sequestration reimbursement reductions.
Enhanced Federal Medical Assistance Percentage (FMAP) - Urged Congress to extend the increased Medicaid FMAP matching rate beyond the public health emergency and increase the enhanced percentage.
Medicaid Fiscal Accountability Regulation - Urged CMS to permanently withdraw the Medicaid Fiscal Accountability Regulation and advocated for Congress to rescind the proposal.
COVID-19 Data Reporting Requirements for Hospitals - Urged HHS ease burden of COVID-19 mandatory reporting requirements and clarify aspects of reporting.
Resident Physician Shortage Reduction Act (S. 348) - Urged Congress to pass the Resident Physician Shortage Reduction Act.
Most Favored Nation - Urged CMS to withdraw or delay the start of the Most-Favored Nation regulation for drug reimbursement for hospitals and other providers.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Jenna |
Stern |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
COVID-19 crisis - Engaged with Congress and the administration to advocate for greater regulatory flexibility and appropriate reimbursement for hospitals through development, passage and ongoing implementation of coronavirus relief legislation:
HEROES Act (H.R. 6800)
Heroes Act 2.0 (H.R. 925)
Health, Economic Assistance, Liability Protection and Schools (HEALS) Act (S. 178)
The Consolidated Appropriations Act (H.R. 133)
Hospital Provider Relief Fund - Urged Congress to provide additional funding for the Provider Relief Fund. Advocated in Congress and with HHS to revert to initial June guidance defining "lost revenue".
Liability protections - Advocated for Congress to include liability protections for health care workers and facilities responding to the COVID-19 crisis.
Front-line Health Care Worker Hazard Pay - Advocated for Congress to provide funding to enhance payment for essential health care workers.
Hospital Group Purchasing - Offered recommendations and insights to support access to essential personal protective equipment, medications and supplies for hospitals treating patients and supply chain stability for the national response to the COVID-19 crisis.
340B Drug Pricing Program - Urged HHS to act to enforce guidance regarding 340B discounts through contract pharmacies.
Vaccine distribution, administration and communications - Advocated to provide states with financial support and other resources to enhance communications and for transparency, including support regarding vaccine distribution, administration and post-market processes, considering both providers needs and states needs.
Surprise Billing - Supported inclusion of provisions to provide for an independent dispute resolution process in legislation to address surprise bills (H.R. 3630; H.R. 2328; S. 1895; H.R. 133). Urged Congress to oppose benchmark payment rates in COVID relief legislation.
Advocated for passage of the Pasteur Act (S. 4760; H.R. 8920)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Jenna |
Stern |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAR
16. Specific lobbying issues
Urged the USTR to extend exclusions for Sec. 301 tariffs until the end of the COVID-19 Public Health Emergency.
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Jenna |
Stern |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |